Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.

Abstract

PURPOSE:

To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH).

DESIGN:

Interventional case series.

METHODS:

Medical records of the 2 patients were reviewed.

RESULTS:

After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period.

CONCLUSIONS:

Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.

• Authors: Yue Wang, Paul A Gaudio
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) 2008 Jul-Aug Vol. 16 Issue 4 Pg. 167-71 ISSN: 1744-5078 [Electronic] England
• PMID: 18716952 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Female
• Fluorescein Angiography
• Humans
• Infliximab
• Male
• Tumor Necrosis Factor-alpha (immunology)
• Uveomeningoencephalitic Syndrome (drug therapy)
• Visual Acuity